1186 related articles for article (PubMed ID: 29415819)
1. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
Sano M
J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
[TBL] [Abstract][Full Text] [Related]
2. Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure.
Scheen AJ
Curr Cardiol Rep; 2019 Jun; 21(8):70. PubMed ID: 31227915
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
Silva Dos Santos D; Polidoro JZ; Borges-JĂșnior FA; Girardi ACC
Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
7. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
8. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
9. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
10. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
Chrysant SG
Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
[TBL] [Abstract][Full Text] [Related]
12. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
[No Abstract] [Full Text] [Related]
13. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
Fattah H; Vallon V
Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
Kashiwagi A; Maegawa H
J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
[TBL] [Abstract][Full Text] [Related]
15. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
Lan NSR; Fegan PG; Yeap BB; Dwivedi G
ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
[TBL] [Abstract][Full Text] [Related]
16. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
17. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Packer M; Anker SD; Butler J; Filippatos G; Zannad F
JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease.
Oguz F; Demoulin N; Thissen JP; Jadoul M; Morelle J
Acta Clin Belg; 2022 Aug; 77(4):805-814. PubMed ID: 34404335
[TBL] [Abstract][Full Text] [Related]
19. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
[TBL] [Abstract][Full Text] [Related]
20. Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke.
Al Hamed FA; Elewa H
Clin Ther; 2020 Nov; 42(11):e242-e249. PubMed ID: 33008610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]